GRAIL to Present at the Canaccord Genuity 46th Annual Growth Conference
Rhea-AI Summary
GRAIL (Nasdaq: GRAL) announced that company management will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11 at 10:00 a.m. ET. Live and replay webcasts of the presentation will be available through the investor relations section of GRAIL's website, with the replay archived for at least 30 days.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 16 | Partnership announcement | Positive | -3.2% | Priority Health offered Galleri testing to self-insured employer groups in Michigan. |
| Jun 25 | Equity financing | Positive | +3.1% | GRAIL completed a $110 million financing with Samsung entities at $70.05 per share. |
| May 31 | Clinical data | Positive | +0.0% | PATHFINDER 2 results covered 35,878 adults and reported increased screen-detected cancers. |
| May 27 | Inducement grants | Neutral | +3.5% | GRAIL granted RSUs covering 34,350 shares to 56 newly hired employees. |
| May 26 | Conference presentation | Neutral | +3.6% | Management announced a June 9 presentation at the Goldman Sachs healthcare conference. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
GRAIL's prior news reactions were mixed: a partnership announcement was followed by -3.23%, while financing and conference-related announcements were followed by positive moves.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.
For more information, visit grail.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-to-present-at-the-canaccord-genuity-46th-annual-growth-conference-302839418.html
SOURCE GRAIL, Inc.